On August 17, 2026, Citius Pharmaceuticals received notice from Nasdaq granting an extension until February 8, 2027, to demonstrate compliance with the $1.00 per share minimum bid price requirement under Listing Rule 5550(a)(2). The company must maintain a closing bid price of at least $1.00 for ten consecutive business days before that date to avoid delisting proceedings. Failure to regain compliance by February 8, 2027, will result in written notice of potential delisting, though the stock continues to trade under the symbol CTXR on the Nasdaq Capital Market while options are evaluated. Citius Pharmaceuticals operates in the biopharmaceutical industry, focusing on the development and commercialization of pharmaceutical products.